🌎 Resumen en español · traducción automática
Un nuevo estudio de la Universidad de Kentucky desafía la creencia tradicional de que los fragmentos óseos en las rodillas de potrillos pura sangre limitan significativamente sus carreras, encontrando que la cirugía artroscópica para remover estos fragmentos hace una diferencia importante en el desempeño y valor de venta. Los investigadores compararon resultados de 46 potrillos con fragmentos óseos contra 138 hermanos sin anomalías radiográficas entre 2015 y 2023, descubriendo que los caballos tratados quirúrgicamente no mostraban diferencias significativas en precio de venta ni ganancias de por vida respecto a caballos sanos, mientras que los no tratados sufrían una penalización importante en la subasta. El estudio sugiere que el costo de la cirugía, aproximadamente 2,000 dólares, se recupera en el precio de venta, haciendo que la intervención sea una decisión financiera sensata para los criadores.
Traducción y resumen generados por IA a partir del artículo en inglés. Puede contener errores; consulte el texto original.
LEXINGTON, Ky. — A new study from the University of Kentucky Maxwell H. Gluck Equine Research Center is upending decades of industry assumptions about thoroughbred yearlings with bone chips in their knees, findings that could reshape sales decisions and preserve the careers of horses historically dismissed as damaged goods.
Published in the Equine Veterinary Journal, the research is the first to directly compare sales and racing outcomes in yearlings with carpal osteochondral fragments—commonly called knee chips or bone chips—against horses with clean radiographs. The results suggest that arthroscopic surgery to remove the fragments makes a meaningful difference, but the condition itself is far less career-limiting than buyers traditionally assume.
“The idea came from seeing a large number of these cases get significantly marked down in price, just because people assume a chip means the horse won’t perform,” said Bruno Menarim, D.V.M., Ph.D., a Gluck Center researcher and one of the study’s senior authors. “That was possibly true in the ’80s and part of the ’90s, but not with current arthroscopic surgery approaches.”
Using clinical records from Hagyard Equine Medical Institute spanning 2015 to 2018, researchers identified 46 thoroughbred yearlings with bone chips. Twenty-six underwent arthroscopic surgery before auction; 20 were managed conservatively. The team compared outcomes for both groups against 138 siblings from the same bloodlines and sale years with no radiographic abnormalities, tracking racing records through June 2023.
The findings paint a nuanced picture. Horses that underwent surgery showed no statistically significant difference in sales price or lifetime earnings compared to clean horses. But yearlings that went to sale untreated were highly penalized at auction and earned significantly less throughout their racing careers—a clear financial distinction that underscores the value of intervention.
The average sales price gap between surgically treated and untreated horses was approximately $2,000—roughly the cost of removing the fragment. “That difference is almost the cost of removing the fragment,” Menarim said. “So go ahead and do the surgery, and you’re increasing the likelihood that this horse is going to have sales appeal—and a better chance of a meaningful racing career.”
For an industry where decisions made at yearling sales have profound financial consequences for owners and breeders, the research offers concrete evidence that early intervention preserves both a horse’s market value and its prospects on the track—a development that could shift how buyers evaluate radiographic findings during auctions.
This article was generated by AI (claude-haiku-4-5-20251001) based on source material from University of Kentucky News, enriched with 3 web searches. The original source is available at https://uknow.uky.edu/research/study-analyzes-buyers-assumptions-about-carpal-chips-thoroughbred-yearlings.
